Clinical trial

A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors

NCT05329298

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2021-07-21

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2021-07-21Date precision: day

Registry last updated2022-04-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Lung Cancerunresolved

Interventions

BPI-361175DRUG

Sponsors & collaborators

Betta Pharmaceuticals Co., Ltd.lead sponsor

Mapped research locations

NanjingJiangsu, China2 ChangshaHunan, China2 ShanghaiShanghai Municipality, China1 HangzhouZhejiang, China1 WuhanHubei, China1 ZhengzhouHenan, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05329298 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.